12,372 trials
Active Systemic Lupus Erythematosus
Primary: Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs) — 11.0; 9.6; 12.9; 12.5 Events per 100 participant years
Heart Failure
Primary: Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12 — 4.9; 9.2 Score on a scale — p=0.016
Sentinel Lymph Node · Melanoma (Skin) · Breast Cancer
Primary: Number of Participants Where the First, Second and Third Sentinel Nodes Localized With the Use of Fluorescence Imaging Alone — 29; 9; 0 Participants
Non Small Cell Lung Cancer · Lung Cancer Stage 1
Primary: Total Morphine Equivalents Consumed — 48; 42.7 MEq
Meniere's Disease
Primary: The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12). — 2.191; 2.415 Definitive Vertigo Day — p=0.623
Migraine Headache
Primary: Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1) — 21.7; 35.6; 22.1; 35.8 percentage of subjects — p=<0.001
Migraine Headache
Primary: Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period) — 25.8; 32.9; 24.6; 32.4 percentage of subjects — p=0.075
Candidemia · Mycoses · Fungal Infection
Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants
Type 2 Diabetes
Primary: Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.44; -2.49; -0.95 Percentage of HbA1c
Cystic Fibrosis
Primary: Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA — 14600; 12600; 16600; 13900 nanograms per milliliter (ng/mL)
Stress Urinary Incontinence
Primary: Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary — 103; 52 Participants
Respiratory Tract Diseases · Abnormal Mucus Secretions
Primary: Change From Baseline to Day 7 of Mean Sputum Viscosity Score of NAC and Placebo — -1.2; -1.0 Score — p=<0.001
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events (TEAE) as Assessed by CTCAE v4.03 — 27; 26; 2; 2 participants
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
First Line Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in…